Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Kim, Sun Young | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Yun, Seong Hyeon | - |
dc.contributor.author | Kim, Hee Cheol | - |
dc.contributor.author | Lee, Woo Yong | - |
dc.contributor.author | Kim, Tae Won | - |
dc.contributor.author | Hong, Yong Sang | - |
dc.contributor.author | Lim, Seok-Byung | - |
dc.contributor.author | Baek, Ji Yeon | - |
dc.contributor.author | Oh, Jae Hwan | - |
dc.contributor.author | Ahn, Joong Bae | - |
dc.contributor.author | Shin, Sang Joon | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Kim, Seong Geun | - |
dc.contributor.author | Kang, Seok Yun | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Zang, Dae Young | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.contributor.author | Choi, In Sil | - |
dc.contributor.author | Kang, Jung Hun | - |
dc.contributor.author | Kim, Min-Ji | - |
dc.contributor.author | Park, Young Suk | - |
dc.date.accessioned | 2024-11-15T19:22:34Z | - |
dc.date.available | 2024-11-15T19:22:34Z | - |
dc.date.issued | 2022-11-20 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.issn | 1527-7755 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/190354 | - |
dc.description.abstract | PURPOSE The combination of oxaliplatin and fluoropyrimidine for 6 months is one of the standard options for adjuvant therapy for high-risk stage II and III colorectal cancers (CRCs). The optimal duration of oxaliplatin to diminish neurotoxicity without compromising efficacy needs to be clarified. PATIENTS AND METHODS This open-label, randomized, phase III, noninferiority trial randomly assigned patients with high-risk stage II and III CRC to 3 and 6 months of oxaliplatin with 6 months of fluoropyrimidine groups (3- and 6-month arms, respectively). The primary end point was disease-free survival (DFS), and the noninferiority margin was a hazard ratio (HR) of 1.25. RESULTS In total, 1,788 patients were randomly assigned to the 6-month (n = 895) and 3-month (n = 893) arms, and 83.6% in the 6-month arm and 85.7% in the 3-month arm completed the treatment. The neuropathy rates with any grade were higher in the 6-month arm than in the 3-month arm (69.5% v 58.3%; P < .0001). The 3-year DFS rates were 83.7% and 84.7% in the 6-month and 3-month arms, respectively, with an HR of 0.953 (95% CI, 0.769 to 1.180; test for noninferiority, P = .0065) within the noninferiority margin. Among patients with stage III CRC treated by capecitabine plus oxaliplatin, the 3-year DFS of the 3-month arm was noninferior as compared with that of the 6-month arm with an HR of 0.713 (95% CI, 0.530 to 0.959; P = .0009). However, among patients with high-risk stage II and stage III CRC treated by infusional fluorouracil, leucovorin, and oxaliplatin, the noninferiority of the 3-month arm compared with the 6-month arm was not proven. CONCLUSION This study suggests that adding 3 months of oxaliplatin to 6 months of capecitabine could be considered an alternative adjuvant treatment for stage III CRC (ClinicalTrials.gov identifier: ). (C) 2022 by American Society of Clinical Oncology | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07 | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1200/JCO.21.02962 | - |
dc.identifier.scopusid | 2-s2.0-85142401178 | - |
dc.identifier.wosid | 000886149800011 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, v.40, no.33, pp 3868 - + | - |
dc.citation.title | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 40 | - |
dc.citation.number | 33 | - |
dc.citation.startPage | 3868 | - |
dc.citation.endPage | + | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | WEEKLY BOLUS FLUOROURACIL | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | DURATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.